Sodium glucose cotransporters inhibitors in type 1 diabetes

Pharmacol Res. 2018 Jul;133:1-8. doi: 10.1016/j.phrs.2018.04.018. Epub 2018 Apr 22.

Abstract

Sodium glucose cotransporter inhibitors (SGLTi) are oral hypoglycemic drugs that reduce renal glucose re-uptake and induce glycosuria. SGLTi have been successfully tested in large randomized clinical trials for type 2 diabetes, and several molecules have been approved in this setting by the international pharmaceutical agencies. Additionally, recent evidence has shown that SGLTi may be useful also in type 1 diabetes (T1D). Indeed, these drugs can be used as an ancillary to insulin to improve glycemic control and reduce insulin dosage, and such regimens have been associated with a lower rate of hypoglycemic episodes. The pharmacological effects of SGLTi therapy are described herein, and we also discuss the future use of SGLTi in T1D.

Keywords: Diabetic kidney disease; Gliflozin; SGLT1; SGLT2; Type 1 diabetes.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Sodium-Glucose Transport Proteins / antagonists & inhibitors*
  • Sodium-Glucose Transport Proteins / metabolism

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transport Proteins